BioRegenx Announces Glycocalyx Biomarkers in Children Study Using Its Medical Testing Device GlycoCheck

CHATTANOOGA, TN / ACCESSWIRE / February 6, 2023 / BioRegenx, Inc. which has entered into a Definitive Agreement to merge with Findit, Inc, and its subsidiary Microvascular Health Solutions, LLC (MVHS), based in Alpine, Utah, announces a new peer-reviewed study published in Pediatric Critical Care Medicine on glycocalyx biomarkers in children with sepsis.

In this study entitled "Endothelial and Glycocalyx Biomarkers in Children With Sepsis After One Bolus of Unbalanced or Balanced Crystalloids," Jaime Fernández-Sarmiento and colleagues from the Department of Pediatrics and Intensive Care, Fundación Cardioinfantil-Instituto de Cardiología, Universidad de La Sabana, Bogotá, Colombia, used the GlycoCheck™ system to test for the effect of different resuscitation fluids on the endothelial glycocalyx in children with sepsis and septic shock.

In this study, the researchers compared two kinds of fluids, so-called Un-Balanced Fluids (0.9% saline with a low pH and high levels of Chloride, UBF) and Balanced Fluids (lactated Ringer or Plasma-Lyte 148, BF). The researchers found that the endothelial glycocalyx is damaged in children with sepsis and septic shock, and that glycocalyx degradation worsens 6 hours after administration of UBF boluses, which is associated with increased vascular permeability, metabolic acidosis, hyperchloremia, and kidney failure.

It was concluded that using the GlycoCheck system to monitor the endothelial glycocalyx in children with sepsis may provide a better understanding of the pathophysiology of sepsis and demonstrated that the GlycoCheck system is a useful tool to monitor the effect of different treatment strategies on the endothelial glycocalyx and associated risks like kidney failure.

"We're excited to add this study in children to the previous studies we've completed with other research groups on sepsis," said Robert Long, CEO of Microvascular Health Solutions and GlycoCheck. "This study, along with previous studies, confirm the undeniable link that sepsis has in degrading the endothelial glycocalyx and reducing microvascular function systemically." Eighteen studies have been conducted on sepsis using GlycoCheck (click here to see the list).

100 Published Studies Have Used GlycoCheck™

GlycoCheck is an FDA registered Class 1 medical testing device. GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score™. It has been used in 100 peer-reviewed research studies worldwide. GlycoCheck is patented in the U.S., Canada, Europe, China, and Japan. MVHS is the exclusive worldwide distributor of GlycoCheck and the upgraded complete GlycoCheck system software, including the new CapiVision™ camera. The new GlycoCheck™ system will shorten testing and calculation time to about 15 minutes.